[go: up one dir, main page]

MX2014010987A - Tratamiento de esclerosis multiple con anticuerpo anti-cd19. - Google Patents

Tratamiento de esclerosis multiple con anticuerpo anti-cd19.

Info

Publication number
MX2014010987A
MX2014010987A MX2014010987A MX2014010987A MX2014010987A MX 2014010987 A MX2014010987 A MX 2014010987A MX 2014010987 A MX2014010987 A MX 2014010987A MX 2014010987 A MX2014010987 A MX 2014010987A MX 2014010987 A MX2014010987 A MX 2014010987A
Authority
MX
Mexico
Prior art keywords
treatment
multiple sclerosis
antibody
cdc
apoptosis
Prior art date
Application number
MX2014010987A
Other languages
English (en)
Inventor
Ronald Herbst
Laura Lee Carter
Yue Wang
Volker Armin Knappertz
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2014010987A publication Critical patent/MX2014010987A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona el tratamiento de la esclerosis múltiple mediante el uso de versiones quiméricas y humanizadas de anticuerpos anti-CD19 que pueden mediar la ADCC, CDC y/o apoptosis.
MX2014010987A 2012-03-12 2013-03-11 Tratamiento de esclerosis multiple con anticuerpo anti-cd19. MX2014010987A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261609704P 2012-03-12 2012-03-12
PCT/US2013/030247 WO2013138244A2 (en) 2012-03-12 2013-03-11 Treatment of multiple sclerosis with anti-cd19 antibody

Publications (1)

Publication Number Publication Date
MX2014010987A true MX2014010987A (es) 2015-03-03

Family

ID=49161934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010987A MX2014010987A (es) 2012-03-12 2013-03-11 Tratamiento de esclerosis multiple con anticuerpo anti-cd19.

Country Status (11)

Country Link
US (1) US20150044168A1 (es)
EP (1) EP2827902A4 (es)
JP (1) JP2015515456A (es)
KR (1) KR20140148411A (es)
CN (1) CN104640560A (es)
AU (1) AU2013232386A1 (es)
CA (1) CA2866943A1 (es)
HK (1) HK1206283A1 (es)
MX (1) MX2014010987A (es)
RU (1) RU2014141056A (es)
WO (1) WO2013138244A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
EP3149046B1 (en) * 2015-07-24 2020-02-26 Innovative Cellular Therapeutics Co., Ltd. Humanized anti-cd19 antibody and use thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
BR112021020924A2 (pt) * 2019-04-24 2022-04-19 Viela Bio Inc Uso de um anticorpo anti-cd19 para tratar doença autoimune

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
MXPA06014069A (es) * 2004-06-04 2007-04-25 Genentech Inc Metodo para tratar esclerosis multiple.
ME01786B (me) * 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
PL2066349T3 (pl) * 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
TW201438738A (zh) * 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
US20120148576A1 (en) * 2009-03-06 2012-06-14 Medlmmune, Llc Humanized anti-cd 19 antibody formulations

Also Published As

Publication number Publication date
CA2866943A1 (en) 2013-09-19
RU2014141056A (ru) 2016-05-10
AU2013232386A1 (en) 2014-10-16
AU2013232386A8 (en) 2014-10-23
KR20140148411A (ko) 2014-12-31
WO2013138244A2 (en) 2013-09-19
HK1206283A1 (en) 2016-01-08
JP2015515456A (ja) 2015-05-28
WO2013138244A8 (en) 2014-09-18
WO2013138244A3 (en) 2014-12-24
CN104640560A (zh) 2015-05-20
EP2827902A4 (en) 2016-01-20
EP2827902A2 (en) 2015-01-28
US20150044168A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
MX2017015042A (es) Anticuerpos cd123 y conjugados de los mismos.
MX2011009312A (es) Formulaciones de anticuerpos humanizados anti-cd19.
MX2022002364A (es) Anticuerpos anti-pd-l1.
ZA201805337B (en) Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
ZA201804077B (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
MX2017011432A (es) Anticuerpos contra cumulo de diferenciacion 48 (cd48) y sus conjugados.
NZ728688A (en) Anti-pd-1 antibodies
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
EP3702372A3 (en) Anti-cd40 human antibodies
EP4368704A3 (en) Cell
MX2016009050A (es) Construcciones biespecificas de union a los antigenos cd3 y cd19.
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
TN2014000107A1 (en) Anti-aplhabetatcr antibody
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
MX2014010987A (es) Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
WO2015009740A3 (en) Anti-mucin 1 binding agents and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EP3609536A4 (en) HUMANIZED ANTI-CD19 ANTIBODY AND USE OF IT WITH CHIMERIC ANTIGEN RECEPTOR
HK1255635A1 (zh) 人源化或嵌合的cd3抗體